Ascletis Pharma Inc. (ASCLETIS-B) released its Monthly Return for the period ended 30 September 2026, detailing marginal changes in share capital and confirming ongoing public-float compliance under Hong Kong Stock Exchange rules.

Authorised Capital • Authorised share capital remained unchanged at 7.00 billion ordinary shares with a par value of USD 0.0001 each, equivalent to total authorised capital of USD 0.70 million.

Issued and Treasury Shares • Issued shares (excluding treasury stock) rose to 1.052 billion, up by 218,014 shares, representing a 0.02 % month-on-month increase. • Treasury shares were unchanged at 5.78 million, keeping total issued shares at 1.058 billion. • Ascletis reconfirmed that its public float comfortably exceeds the 25 % minimum threshold prescribed by HKEX Main Board Rule 13.32B.

Equity Incentive Activity • The entire share increase stemmed from option exercises under the 2019 Share Option Scheme. – Options exercised: 218,014 – Cash proceeds: HKD 0.48 million. • Post-exercise, outstanding options under the 2019 scheme declined to 6.04 million. • The 2025 Share Option Scheme remains untouched this month, with 5.45 million options outstanding and capacity to issue up to 33.09 million additional shares.

Share Repurchase Status • A cumulative 2.15 million shares previously repurchased between 30 June and 30 July 2026 for cancellation had not yet been cancelled as of 30 September 2026; these shares are disclosed separately and do not affect the month’s issued-share movement.

Liquidity Outlook • With negligible dilution (0.02 %) and stable treasury levels, Ascletis-B’s capital structure remains largely intact. Ongoing share-based-payment activity continues to be modest, and the company’s adherence to HKEX public-float requirements underpins orderly trading conditions.